Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 13/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771920 | 0.88 | GRM4 (0.56) | GRM4EGFRABL1ABL2FADS1 | |
| SCHEMBL3763899 | 0.87 | GRM4 (0.51) | GRM4LRRK2EGFR | |
| SCHEMBL3774794 | 0.81 | GRM4 (0.50) | GRM4LRRK2EGFRABL1ABL2 | |
| SCHEMBL3775329 | 0.81 | LRRK2 (0.61) | GRM4LRRK2EGFR | |
| SCHEMBL3775900 | 0.81 | GRM4 (0.48) | GRM4LRRK2 | |
| SCHEMBL3775310 | 0.81 | GRM4 (0.57) | GRM4LRRK2EGFR | |
| SCHEMBL13060922 | 0.81 | MAPT (0.45) | GRM4LRRK2 | |
| SCHEMBL3768341 | 0.80 | GRM4 (0.59) | GRM4LRRK2EGFRABL1ABL2 | |
| SCHEMBL3775370 | 0.79 | LRRK2 (0.63) | GRM4LRRK2 | |
| SCHEMBL3762265 | 0.78 | GRM4 (0.54) | GRM4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | GRM4 1109/4885LRRK2 2309/4885EGFR 106/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | GRM4 1107/4885LRRK2 2208/4885EGFR 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.